Royal College of Surgeons in Ireland
Browse
DOCUMENT
The role of genetic and epigenetic alterations in neuroblastoma d.pdf (543.34 kB)
PRESENTATION
Cronology of neuroblastoma.pptx (85.84 kB)
1/0
2 files

The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Version 2 2022-03-21, 12:42
Version 1 2019-11-23, 10:34
journal contribution
posted on 2022-03-21, 12:42 authored by Raquel Domingo-Fernandez, Karen Watters, Olga PiskarevaOlga Piskareva, Raymond StallingsRaymond Stallings, Isabella Bray

Neuroblastoma is a highly heterogeneous tumor accounting for 15 % of all pediatric cancer deaths. Clinical behavior ranges from the spontaneous regression of localized, asymptomatic tumors, as well as metastasized tumors in infants, to rapid progression and resistance to therapy. Genomic amplification of the MYCN oncogene has been used to predict outcome in neuroblastoma for over 30 years, however, recent methodological advances including miRNA and mRNA profiling, comparative genomic hybridization (array-CGH), and whole-genome sequencing have enabled the detailed analysis of the neuroblastoma genome, leading to the identification of new prognostic markers and better patient stratification. In this review, we will describe the main genetic factors responsible for these diverse clinical phenotypes in neuroblastoma, the chronology of their discovery, and the impact on patient prognosis.

History

Comments

The final publication is available at http://link.springer.com

Published Citation

Domingo-Fernandez R, Watters K, Piskareva O, Stallings RL, Bray I. The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatric Surgery International. 2013 Feb;29(2):101-19.

Publication Date

2013-02-01

PubMed ID

23274701

Department/Unit

  • School of Pharmacy and Biomolecular Sciences

Usage metrics

    Royal College of Surgeons in Ireland

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC